Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses OMER in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named OMER in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Gregory Demopulos | $972,525 | $972,525 | $0 | $2,207,974 | $0 | $0 | $24,984 | $4,178,008 |
| President, Chief Executive Officer and Chairman of the Board | ||||||||
| Peter Cancelmo | 489,480 | 171,318 | 0 | 255,257 | 0 | 0 | 4,647 | 920,702 |
| Vice President, General Counsel and Secretary | ||||||||
| David Borges | 325,600 | 113,750 | 0 | 242,494 | 0 | 0 | 4,430 | 686,274 |
| Vice President, Finance, Chief Accounting Officer and Treasurer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Gregory Demopulos | $4,178,008 | $3,764,151 | $7,689,843 | +413,857 |
| Peter Cancelmo | 920,702 | 906,894 | 852,633 | +13,808 |
| David Borges | 686,274 | 627,907 | — | +58,367 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Thomas J. Cable | Director | 2026-05-22 | A | 7,500 | $11 | $81,300 | Common | Form 4 ↗ |
| Thomas J. Cable | Director | 2026-05-22 | D | 7,500 | 12 | 87,039 | Common | Form 4 ↗ |
| Thomas J. Cable | Director | 2026-05-22 | D | 7,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Thomas J. Cable | Director | 2026-06-18 | A | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Thomas F. Bumol | Director | 2026-06-18 | A | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Leroy E. Hood MD PhD | Director | 2026-06-18 | A | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gregory Demopulos | Director | 2026-06-18 | A | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Diana T. Perkinson | Director | 2026-06-18 | A | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Rajiv Shah | Director | 2026-06-18 | A | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Arnold C. Hanish | Director | 2026-06-18 | A | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Peter Cancelmo | VP, General Counsel | 2026-07-22 | A | 105,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Borges | VP, Finance & CAO | 2026-07-22 | A | 105,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gregory Demopulos | Director | 2026-07-22 | A | 1,000,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Gregory Demopulos | OPTION | 2025-06-30 | — | — | 865,000 | — | $2,207,974 |
| Peter Cancelmo | OPTION | 2025-06-30 | — | — | 100,000 | — | 255,257 |
| David Borges | OPTION | 2025-06-30 | — | — | 95,000 | — | 242,494 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Gregory Demopulos | $0 | $0 | $2,207,974 | 0.0% |
| Peter Cancelmo | 0 | 0 | 255,257 | 0.0% |
| David Borges | 0 | 0 | 242,494 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Gregory Demopulos | Option | 54,167 | 3.93 | — |
| David Borges | Option | 8,333 | 2.94 | — |
| David Borges | Option | 55,417 | 3.06 | — |
| Peter Cancelmo | Option | 6,667 | 3.93 | — |
| David Borges | Option | 79,167 | 3.2 | — |
| David Borges | Option | 1,667 | 3.93 | — |
| Gregory Demopulos | Option | 720,833 | 3.2 | — |
| Gregory Demopulos | Option | 422,917 | 3.06 | — |
| Peter Cancelmo | Option | 33,333 | 2.94 | — |
| Peter Cancelmo | Option | 58,333 | 3.06 | — |
| Peter Cancelmo | Option | 83,333 | 3.2 | — |
| Gregory Demopulos | Option | 238,333 | 2.94 | — |
We orient our executive compensation program to: Provide total compensation opportunities that enable us to recruit and retain executives with the experience and skills needed to manage the growth of our company and lead us to the next stage of development. Establish a clear alignment between the interests of our executives and the interests of our shareholders. Reinforce a culture of ownership, excellence and urgency. Create a direct and meaningful link between company business results, individual performance and compensation.
| CEO STI target (% of salary) | 100% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Compensia |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-18 | 24,384,445 | 6,856,592 | 507,821 | 78.05% | Passed |
| 2025 | 2025-06-27 | 15,086,368 | 1,856,643 | 615,511 | 89.04% | Passed |
| 2024 | 2024-06-06 | 15,849,545 | 6,977,695 | 468,294 | 69.43% | Passed |
| 2023 | 2023-06-23 | 20,792,271 | 2,594,301 | 405,177 | 88.91% | Passed |
| 2020 | 2020-06-05 | 25,967,469 | 1,316,736 | 603,553 | 95.17% | Passed |
| 2017 | 2017-06-22 | 16,084,478 | 3,980,923 | 364,111 | 80.16% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-18 | 78.05%a |
| 2025 | 2025-06-27 | 89.04%b |
| 2024 | 2024-06-06 | 69.43%c |
a. Approved under the standard stated in the filing — “Accordingly, abstentions will not affect the determination of the directors who have received the highest number of affirmative votes or whether the votes cast in favor of Proposals 2, 3 or 4 exceed those cast against each such proposal.”.
b. Approved under the standard stated in the filing — “Accordingly, abstentions will not affect the determination of the directors who have received the highest number of affirmative votes or whether the votes cast in favor of Proposals 2 or 3 exceed those cast against each such proposal.”.
c. Approved under the standard stated in the filing — “Accordingly, abstentions will not affect the determination of the directors who have received the highest number of affirmative votes or whether the votes cast in favor of Proposals 2 or 3 exceed those cast against each such proposal.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 21.8 : 1 |
|---|---|
| CEO total compensation | $4,178,008 |
| Median employee compensation | $191,656 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Thomas J. CableIndependent · Lead Independent Director · Audit · Compensation (Chair) · Nominating and Governance (Chair) | $110,000 | $0 | $41,060 | — | $0 | $151,060 |
| Rajiv Shah, M.DIndependent · Audit · Compensation | 72,500 | 0 | 41,060 | — | 0 | 113,560 |
| Arnold C. HanishIndependent · Audit (Chair) | 70,000 | 0 | 41,060 | — | 0 | 111,060 |
| Leroy E. Hood, M.D., Ph.DIndependent · Compensation · Nominating and Governance · Scientific | 67,500 | 0 | 41,060 | — | 0 | 108,560 |
| Diana T. Perkinson, M.DIndependent · Nominating and Governance · Scientific | 60,000 | 0 | 41,060 | — | 0 | 101,060 |
| Thomas F. Bumol, Ph.DIndependent · Scientific (Chair) | 60,000 | 0 | 41,060 | — | 0 | 101,060 |
| Peter A. Demopulos, M.DNot independent · Scientific | 55,000 | 0 | 41,060 | — | 0 | 96,060 |
| Gregory A. Demopulos, M.DEmployee director · Board Chair | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $41,060 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 20,000 / 20,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $495,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $495,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Omeros names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Omeros.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Pacira BioSciences, Inc. | 2025 | Frank Lee | $935,308 | $9,215,500 | $0 | $738,810 | $11,636,917 |
| 2 | Arcus Biosciences, Inc. | 2025 | Terry Rosen | 775,000 | 2,199,450 | 6,008,860 | 658,750 | 9,656,813 |
| 3 | Agios Pharmaceuticals, Inc. | 2025 | Brian Goff | 846,864 | 1,291,680 | 2,627,252 | 592,804 | 5,370,389 |
| 4 | Omeros | 2025 | Gregory Demopulos | 972,525 | 0 | 2,207,974 | 0 | 4,178,008 |
| 5 | Vanda Pharmaceuticals, Inc. | 2025 | Mihael Polymeropoulos | 965,655 | 2,007,000 | 0 | 834,326 | 3,851,468 |
| 6 | Esperion Therapeutics, Inc. | 2025 | Sheldon Koenig | 770,833 | 1,260,000 | 847,929 | 639,375 | 3,535,512 |
| 7 | Aclaris Therapeutics, Inc. | 2025 | Neal Walker | 615,000 | 828,426 | 1,581,615 | 350,550 | 3,375,591 |
| 8 | Enanta Pharmaceuticals, Inc. | 2025 | Jay Luly | 803,300 | 128,550 | 1,223,975 | 591,665 | 2,769,548 |
| 9 | Karyopharm Therapeutics | 2025 | Richard Paulson | 770,000 | 838,996 | 241,544 | 350,350 | 2,320,902 |
| 10 | Ironwood Pharmaceuticals, Inc. | 2025 | Thomas McCourt | 867,568 | 411,696 | 0 | 650,676 | 1,948,390 |
| 11 | Collegium Pharmaceutical, | 2025 | Vikram Karnani | 875,000 | 0 | 0 | 835,406 | 1,715,846 |
| 12 | Mersana Therapeutics, Inc. | 2024 | Michael Huber | 632,500 | 133,635 | 518,044 | 322,575 | 1,613,754 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Omeros | 100% | Options 100 | not disclosed | Compensia |
| Aclaris Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Pearl Meyer |
| Agios Pharmaceuticals, Inc. | 100% | Options 40 · PSU 40 · RSU 20 | No | Aon |
| Arcus Biosciences, Inc. | 100% | Options 67 · RSU 33 | not disclosed | Radford |
| Collegium Pharmaceutical, | 127.3% | RSU 70 · PSU 30 | Yes — relative ranking of the total shareholder return (TSR) of the Company's common stock in 2025, 2026, 2027 and the cumulative three-year performance period (2025-2027) return relative to the TSR of peer companies within the S&P Pharmaceutical Select Industry Index | Alpine Rewards, LLC |
| Enanta Pharmaceuticals, Inc. | not disclosed | Options 80 · PSU 10 · MSU 10 | No | Alpine Rewards LLC |
| Esperion Therapeutics, Inc. | 110% | not disclosed | not disclosed | not disclosed |
| Ironwood Pharmaceuticals, Inc. | 100% | PSU 50 · RSU 50 | Yes — relative total stockholder return (rTSR) | Alpine Rewards LLC |
| Karyopharm Therapeutics | 90% | not disclosed | Yes — Relative TSR | Alpine Rewards, LLC (through September 2025); Willis Towers Watson (beginning August 2025) |
| Mersana Therapeutics, Inc. | 85% | Options 75 · RSU 25 | not disclosed | Pearl Meyer & Partners, LLC |
| Pacira BioSciences, Inc. | 90% | RSU 100 | No | Aon (Aon plc, Human Capital Solutions practice) |
| Vanda Pharmaceuticals, Inc. | 108% | not disclosed | Yes — Relative TSR | Willis Towers Watson |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Gregory Demopulos | DEF 14A | 2026-04-30 | 0001552781-26-000281 | Section “Summary Compensation Table”. As printed: 4,178,008. Filing ↗machine: t160 · r1 · c6 · span 462502–462511 |
| 2 | Section 01, Peter Cancelmo | DEF 14A | 2026-04-30 | 0001552781-26-000281 | Section “Summary Compensation Table”. As printed: 920,702. Filing ↗machine: t160 · r6 · c6 · span 472235–472242 |
| 3 | Section 01, David Borges | DEF 14A | 2026-04-30 | 0001552781-26-000281 | Section “Summary Compensation Table”. As printed: 686,274. Filing ↗machine: t160 · r4 · c6 · span 468201–468208 |
| 4 | Section 03, Gregory Demopulos OPTION | DEF 14A | 2026-04-30 | 0001552781-26-000281 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t167 · r1 · c5 · span 488840–488849 |
| 5 | Section 03, Peter Cancelmo OPTION | DEF 14A | 2026-04-30 | 0001552781-26-000281 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t167 · r3 · c5 · span 491713–491720 |
| 6 | Section 03, David Borges OPTION | DEF 14A | 2026-04-30 | 0001552781-26-000281 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t167 · r2 · c5 · span 490264–490271 |
| 7 | Section 07, pay ratio | DEF 14A | 2026-04-30 | 0001552781-26-000281 | Section “CEO Pay Ratio”. As printed: 21.8 : 1. Filing ↗ |
| 8 | Section 08, Thomas J. Cable | DEF 14A | 2026-04-30 | 0001552781-26-000281 | Section “Director Compensation”. As printed: 151,060. Filing ↗machine: t111 · r2 · c3 · span 328349–328356 |
| 9 | Section 08, Rajiv Shah, M.D | DEF 14A | 2026-04-30 | 0001552781-26-000281 | Section “Director Compensation”. As printed: 113,560. Filing ↗machine: t111 · r7 · c3 · span 333326–333333 |
| 10 | Section 08, Arnold C. Hanish | DEF 14A | 2026-04-30 | 0001552781-26-000281 | Section “Director Compensation”. As printed: 111,060. Filing ↗machine: t111 · r4 · c3 · span 330332–330339 |
| 11 | Section 08, Leroy E. Hood, M.D., Ph.D | DEF 14A | 2026-04-30 | 0001552781-26-000281 | Section “Director Compensation”. As printed: 108,560. Filing ↗machine: t111 · r5 · c3 · span 331330–331337 |
| 12 | Section 08, Diana T. Perkinson, M.D | DEF 14A | 2026-04-30 | 0001552781-26-000281 | Section “Director Compensation”. As printed: 101,060. Filing ↗machine: t111 · r6 · c3 · span 332326–332333 |
| 13 | Section 08, Thomas F. Bumol, Ph.D | DEF 14A | 2026-04-30 | 0001552781-26-000281 | Section “Director Compensation”. As printed: 101,060. Filing ↗machine: t111 · r1 · c3 · span 327361–327368 |
| 14 | Section 08, Peter A. Demopulos, M.D | DEF 14A | 2026-04-30 | 0001552781-26-000281 | Section “Director Compensation”. As printed: 96,060. Filing ↗machine: t111 · r3 · c3 · span 329345–329351 |
| 15 | Section 08, Gregory A. Demopulos, M.D | DEF 14A | 2026-04-30 | 0001552781-26-000281 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 16 | Section 02, Thomas J. Cable 2026-05-22 | Form 4 | 2026-05-27 | 0001437749-26-018625 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 17 | Section 02, Thomas J. Cable 2026-05-22 | Form 4 | 2026-05-27 | 0001437749-26-018625 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 18 | Section 02, Thomas J. Cable 2026-05-22 | Form 4 | 2026-05-27 | 0001437749-26-018625 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 19 | Section 02, Thomas J. Cable 2026-06-18 | Form 4 | 2026-06-22 | 0001437749-26-021235 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 20 | Section 02, Thomas F. Bumol 2026-06-18 | Form 4 | 2026-06-22 | 0001437749-26-021234 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 21 | Section 02, Leroy E. Hood MD PhD 2026-06-18 | Form 4 | 2026-06-22 | 0001437749-26-021238 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 22 | Section 02, Gregory Demopulos 2026-06-18 | Form 4 | 2026-06-22 | 0001437749-26-021236 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 23 | Section 02, Diana T. Perkinson 2026-06-18 | Form 4 | 2026-06-22 | 0001437749-26-021239 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 24 | Section 02, Rajiv Shah 2026-06-18 | Form 4 | 2026-06-22 | 0001437749-26-021240 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 25 | Section 02, Arnold C. Hanish 2026-06-18 | Form 4 | 2026-06-22 | 0001437749-26-021237 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 02, Peter Cancelmo 2026-07-22 | Form 4 | 2026-07-24 | 0001437749-26-024441 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, David Borges 2026-07-22 | Form 4 | 2026-07-24 | 0001437749-26-024439 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, Gregory Demopulos 2026-07-22 | Form 4 | 2026-07-24 | 0001437749-26-024443 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 06, 2026 vote | Form 8-K | 2026-06-25 | 0001437749-26-021617 | Item 5.07 · say-on-pay result. As reported: 78.05% (votes for as printed: 24,384,445). Filing ↗ |
| 30 | Section 06, 2025 vote | Form 8-K | 2025-07-02 | 0001437749-25-021959 | Item 5.07 · say-on-pay result. As reported: 89.04% (votes for as printed: 15,086,368). Filing ↗ |
| 31 | Section 06, 2024 vote | Form 8-K | 2024-06-12 | 0001437749-24-020102 | Item 5.07 · say-on-pay result. As reported: 69.43% (votes for as printed: 15,849,545). Filing ↗ |
| 32 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 33 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 34 | Section 09b board cost (computed) | Computed | — | computed | Cash 495,000 + equity 0 + all other 0 = 495,000, summed across the director compensation table rows.machine: formula: Σ = 495,000 |
| 35 | Pacira BioSciences, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001104659-26-050353 | CEO total compensation as printed in Pacira BioSciences, Inc.'s own proxy. As printed: 11,636,917. Filing ↗machine: t136 · r1 · c47 · span 2412158–2412168 |
| 36 | Arcus Biosciences, Inc., Section 10b CEO total | DEF 14A | 2026-04-21 | 0001724521-26-000025 | CEO total compensation as printed in Arcus Biosciences, Inc.'s own proxy. As printed: 9,656,813. Filing ↗machine: r2 · c48 · span 403740–403749 |
| 37 | Agios Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177086 | CEO total compensation as printed in Agios Pharmaceuticals, Inc.'s own proxy. As printed: 5,370,389. Filing ↗machine: r2 · c31 · span 613185–613194 |
| 38 | Omeros (subject), Section 10b CEO total | DEF 14A | 2026-04-30 | 0001552781-26-000281 | CEO total compensation as printed in Omeros's own proxy. As printed: 4,178,008. Filing ↗machine: t160 · r1 · c6 · span 462502–462511 |
| 39 | Vanda Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001628280-26-026893 | CEO total compensation as printed in Vanda Pharmaceuticals, Inc.'s own proxy. As printed: 3,851,468. Filing ↗machine: span 563696–563705 |
| 40 | Esperion Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-16 | 0001628280-26-025499 | CEO total compensation as printed in Esperion Therapeutics, Inc.'s own proxy. As printed: 3,535,512. Filing ↗machine: span 423838–423847 |
| 41 | Aclaris Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001104659-26-047262 | CEO total compensation as printed in Aclaris Therapeutics, Inc.'s own proxy. As printed: 3,375,591. Filing ↗machine: r2 · c14 · span 317880–317889 |
| 42 | Enanta Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-01-26 | 0001193125-26-022558 | CEO total compensation as printed in Enanta Pharmaceuticals, Inc.'s own proxy. As printed: 2,769,548. Filing ↗machine: r2 · c16 · span 830357–830366 |
| 43 | Karyopharm Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-13 | 0001503802-26-000023 | CEO total compensation as printed in Karyopharm Therapeutics's own proxy. As printed: 2,320,902. Filing ↗machine: r2 · c29 · span 1192339–1192348 |
| 44 | Ironwood Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001104659-26-050325 | CEO total compensation as printed in Ironwood Pharmaceuticals, Inc.'s own proxy. As printed: 1,948,390. Filing ↗machine: t29 · r1 · c48 · span 584182–584191 |
| 45 | Collegium Pharmaceutical,, Section 10b CEO total | DEF 14A | 2026-04-07 | 0001628280-26-024063 | CEO total compensation as printed in Collegium Pharmaceutical,'s own proxy. As printed: 1,715,846. Filing ↗machine: r2 · c48 · span 779394–779403 |
| 46 | Mersana Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2025-04-29 | 0001104659-25-040448 | CEO total compensation as printed in Mersana Therapeutics, Inc.'s own proxy. As printed: 1,613,754. Filing ↗machine: t16 · r1 · c41 · span 608188–608197 |
| 47 | Section 10a, Pacira BioSciences, Inc. reciprocity | DEF 14A | — | 0001104659-26-050353 | Pacira BioSciences, Inc.'s most recent proxy was read; its disclosed peer group does not include Omeros. Filing ↗ |
| 48 | Section 10a, Vanda Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001628280-26-026893 | Vanda Pharmaceuticals, Inc. names Omeros in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 49 | Section 10a, Collegium Pharmaceutical, reciprocity | DEF 14A | — | 0001628280-26-024063 | Collegium Pharmaceutical,'s most recent proxy was read; its disclosed peer group does not include Omeros. Filing ↗ |
| 50 | Section 10a, Enanta Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001193125-26-022558 | Enanta Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Omeros. Filing ↗ |
| 51 | Section 10a, Mersana Therapeutics, Inc. reciprocity | DEF 14A | — | 0001104659-25-040448 | Mersana Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Omeros. Filing ↗ |
| 52 | Section 10a, Agios Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001193125-26-177086 | Agios Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Omeros. Filing ↗ |